Body Roundness Index Trajectory Tied to Risk for Cardiovascular Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 30, 2024 -- A higher body roundness index (BRI) trajectory is associated with an increased risk for cardiovascular disease (CVD), according to a study published online Sept. 25 in the Journal of the American Heart Association.
Man Yang, M.D., from The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University in China, and colleagues examined the association of BRI trajectories with CVD among 9,935 middle-aged and older Chinese people in a longitudinal cohort. Group-based trajectory modeling was used to identify BRI trajectories.
Participants were classified into low-stable, moderate-stable, and high-stable BRI trajectories, accounting for 49.81, 42.35, and 7.84 percent of the study population, respectively. The researchers found that participants in the moderate-stable and high-stable BRI trajectory groups had an increased risk for CVD compared with participants in the low-stable trajectory group, with multivariable adjusted hazard ratios of 1.22 and 1.55, respectively. CVD risk reclassification was improved by simultaneously adding the BRI trajectory to the conventional risk model.
"The longitudinal trajectory of the BRI could be used as a novel indicator of CVD risk, providing a new possibility for CVD prevention," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-01 06:00
Read more
- Risk for Mortality Up With Low Income in Type 2 Diabetes
- Quitting Smoking After Cancer Diagnosis Boosts Survival by Up to 26%
- Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
- Higher Heart Rate May Help Spur A-fib in Black Patients
- Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023
- Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions